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Abstract. Anemia in the elderly is a common but challenging clinical scenario. Here we describe 
the case of an older woman who presented with anemia and elevated inflammation markers. 
After a complete diagnostic work-up, a definite etiology of the anemia could not be found so 
eventually a bone marrow biopsy was performed and she was diagnosed with myelodysplastic 
syndrome. She responded well to erythropoietin treatment but her inflammation markers 
remained elevated thus a positron emission tomography was performed. It turned out that the 
patient suffered from giant cell artheritis and her anemia completely resolved after steroid 
treatment. Our case outlines that it is necessary to pay particular attention to anemia of 
inflammation, which could be due to several and often masked conditions. Myelodysplatic 
syndromes should be considered when other causes have been ruled out, but their diagnosis can 
be difficult and requires expertise in the field. 
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Introduction. Anemia in the elderly is a very common 
condition that contributes to morbidity and mortality 
and significantly impairs quality of life. In the Third 
National Health and Nutrition Examination Survey 
(NHANES III) study the incidence of anemia in men 
and women older than 65 was 11% and 10.2%, 
respectively,¹ thus representing a problem almost every 
physician deals with. Several causes often contribute to 
anemia in this age group, and it is not always possible 
to find a unifying diagnosis,
2
 hence it frequently 
represents a challenging clinical scenario. Here we 
present the case of an elderly Italian woman 
investigated for persistent anemia and elevated 
inflammation markers.  
 
Case Report.  
Case presentation: A 68 year old woman was admitted 
to a primary care center for worsening asthenia and 
fatigability. During the two months before admission, 
she also referred weight loss, mild fever, and cough. 
Clinical history: She was diagnosed with ovarian 
cancer 13 years before, and she was treated with 
surgery and a carboplatin-containing chemotherapy 
regimen. No signs of disease recurrence were found 
afterwards. She suffered from hypertension, well 
controlled with medical therapy, arthrosis, and chronic 
constipation. 
 
Initial work-up: At admission clinical examination was 
unremarkable. Blood count showed severe normocytic 
anemia (hemoglobin 7.5g/dL, mean corpuscular 
volume 90 fL) and mild thrombocytosis (platelets 
452000/µL) while reticulocyte count, leucocyte count, 
and differential were normal. Iron or vitamin 
deficiency were ruled out, and lactate dehydrogenase, 
serum creatinine, thyroid functioning and liver tests 
were normal. Reactive C protein (RCP), erythrocyte 
sedimentation rate (ESR) and serum ferritin, however, 
were significantly increased (18.2 mg/dL, 160 mm/h 
and 1136 ng/mL, respectively).  
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Differential diagnosis: Nutritional deficiencies (i.e. 
lack of iron, vitamin B12 or folic acid), chronic kidney 
disease, thalassemia trait and inflammation are the 
most frequent causes of anemia in elderly patients and 
should be considered first.
3
 Hemolysis, radio- and 
chemo-therapeutic interventions, hypothyroidism or 
hepatic insufficiency are other common causes that 
should be ruled out. Anemia due to inflammation (AI) 
is maybe the most complex one. As a matter of fact, 
several pathophysiological mechanisms are involved 
such as disturbance of iron homeostasis, impaired 
proliferation of erythroid progenitor cells and reduced 
erythropoietin response. Furthermore, the causes of 
inflammation are often multiple and not always the 
source is apparent (e.g. inflammatory bowel disease, 
rheumatologic disorders, cancer, infections).
4 
 
Besides, AI can mask iron deficiency because, in 
the presence of both these conditions, the commonly 
used serum iron-status indicators (namely iron, 
transferrin, transferrin saturation and ferritin) can be 
difficult to interpret.
3 
The discovery of hepcidin, the 
main regulator of iron homeostasis, significantly 
improved our understanding of the pathophysiology of 
AI and the measurement of serum hepcidin level, 
which is down-regulated in case of iron deficiency and 
up-regulated in presence of inflammation, soon could 
become a useful tool in the diagnostic work-up of 
anemia in the elderly.
5
 
 
Further examinations: Since inflammation markers 
remained elevated in our patient, other investigations 
were performed to rule out an infection, an 
autoimmune disease or malignancy: microbiological 
tests were negative, autoimmunity tests showed a low 
antinuclear antibody titer and a weak rheumatoid factor 
positivity, chest, and abdomen computed tomography 
and echocardiography were normal. Anemia persisted, 
no precise inflammatory source could be found and a 
bone marrow (BM) trephine biopsy was eventually 
performed and evaluated by the local pathologist. It 
showed a hypercelullar bone marrow with trilinear 
dysplasia, abnormal localization of immature 
precursors and 1.5% of blasts. She was diagnosed with 
myelodysplastic syndrome (MDS)-unspecified, without 
blast excess, likely secondary to chemotherapy 
exposure. Cytogenetic analysis and BM aspiration were 
not performed. 
 
Differential diagnosis: A BM dysfunction, either 
primary, such as MDS, or secondary to neoplastic or 
infectious agents, should be considered after ruling out 
all other causes of anemia. MDS are suspected in 
elderly patients in case of unexplained cytopenia, more 
commonly isolated macrocytic anemia, and confirmed 
with a BM aspirate and biopsy.  
 
Hematologic follow-up: The patient was then 
discharged and referred to our center. When she 
presented to our clinic, she was afebrile, reported 
fatigue and weakness. Her blood count was stable with 
isolated anemia requiring weekly transfusions and ESR 
and RCP remained elevated. In order to confirm the 
diagnosis, we proposed her a new BM evaluation with 
morphological and cytogenetic analysis but the patient 
refused it. As per our policy, we tested the blood level 
of  Wilms tumor gene transcript (frequently elevated in 
acute myeloid leukemia and MDS)
 6 ,
 and it was in the 
normal range. Giving the diagnosis of low risk MDS 
with isolated anemia, we checked serum erythropoietin 
level, that resulted in the reference range but 
inadequate for the degree of anemia (31.7 mUI/mL), 
therefore we started the patient on recombinant 
erythropoietin, 40000 U weekly. Her anemia 
progressively improved and she achieved an erythroid 
response
7
 after 3 weeks of treatment, becoming 
transfusion independent.  
 
Final diagnosis: So far it could have looked like a 
typical low-risk MDS responsive to erythropoietin. 
However, the patient was still complaining of 
arthralgias and ESR and RCP remained elevated. 
Moreover, she reported the appearance of a livedo 
reticularis on her lower limbs. To better clarify the 
case, given the persistently elevated inflammation 
markers and the personal history of ovarian cancer, a 
total body positron emission tomography (PET) was 
performed. Surprisingly, it revealed a dishomogeneous 
and intense hyperfixation in the wall of medium and 
big arterial vessels, consistent with a vascular 
inflammatory process (Figure 1). We referred the 
patient to a rheumatologist, and she underwent a biopsy 
of the temporal artery which revealed histology 
consistent with giant cell arteritis (GCA). 
Erythropoietin was discontinued; she was started on 
corticosteroid therapy and her anemia rapidly resolved. 
Seven years after GCA diagnosis our patient is doing 
well, with normal blood counts and without any further 
therapy. 
 
Discussion. In the case we are presenting, the initial 
work-up of our patient demonstrated severe anemia 
associated with significantly elevated inflammation 
markers, prompting the diagnosis of AI. However, 
even though several examinations were performed, a 
clear etiology could not be found and eventually the 
patient underwent a BM biopsy. The diagnosis seemed 
to be MDS. 
MDS usually present with anemia, isolated or 
combined with neutropenia and thrombocytopenia,
8
 but 
anemia and thrombocytosis can seldom occur.
9,10
 
Anemia is usually macrocytic (rarely it can be 
normocytic or even microcytic),
11
 reticulocyte count is 
(relatively) reduced, there can be signs of
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Figure 1. The total body positron emission tomography (PET) revealed a dishomogeneous and intense hyperfixation in the wall of medium 
and big arterial vessels. 
 
dyserithropoiesis and serum ferritin level can be 
elevated. On peripheral blood smear a dimorphic red-
cell population that includes oval macrocytes can be 
seen, often together with neutrophils or platelets 
abnormalities (e.g. hypogranulated neutrophils or 
pseudo Pelger–Huët cells).8 MDS diagnosis is 
confirmed by performing a BM examination. It is 
important to carry out both BM aspirate and trephine 
biopsy as the first one is essential to evaluate cellular 
morphology and to count the proportion of blasts while 
the latter allows for determination of BM cellularity 
and architecture.
12
 Indeed the pathological hallmark of 
MDS is BM dysplasia that can only be assessed by 
morphology, which represents the most important tool 
to establish a definite diagnosis.
13
 The 2008 World 
Health Organization classification of MDS requires the 
demonstration of unequivocal dysplasia in at least 10% 
of the cells of the erythroid, granulocytic or 
megakaryocytic lineage.
14
 However, nutritional 
deficiencies, medications, toxins, growth factor 
therapy, inflammation or infections can sometimes 
cause secondary dysplasia and thus they should be 
excluded before a diagnosis of MDS is established. In 
the cases of MDS with an excess of blasts or with more 
than 15% of ring sideroblasts in the erythroid 
precursors the diagnosis is usually straightforward. In 
the other cases, the morphologic evidence of dysplasia 
may not be unequivocal, and the presence of a specific 
cytogenetic abnormality or the immunophenotyping 
can be helpful in confirming the diagnosis.
14,15
 If 
unilinear dysplasia is the only proven sign of 
myelodysplasia an observation period of 6 months and 
a second BM investigation is recommended to establish 
a definite MDS diagnosis.
14
 The complexity of 
diagnosis of MDS can lead to mistakes and significant 
discrepancies between peripheral and tertiary care 
centers have been outlined.
16,17
 Therefore, it appears 
important that an experienced hematologist along with 
an hemopatologist establish the diagnosis of MDS and 
a discussion with other colleagues experts in this field 
could be useful when in doubt. 
Our patient was eventually diagnosed with GCA. 
GCA can present with typical symptoms such as a 
headache, jaw and tongue claudication, scalp 
tenderness, visual disturbance and manifestations of 
polymyalgia rheumatica
18
 and the diagnosis still relies 
on the 1990 American College of Rheumatology 
classification criteria [3 of the following 5 criteria are 
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required: 1) age 50 years or older, 2) new-onset 
localized headache, 3) temporal artery tenderness or 
decreased temporal artery pulse, 4) ESR of at least 50 
mm/h, 5) abnormal artery biopsy specimen 
characterized by mononuclear infiltration or 
granulomatous inflammation].
19
 However, the 
diagnosis of GCA can be difficult due to the variability 
of clinical presentation, and the utility of these criteria 
in clinical practice has been questioned.
20 
Furthermore, 
the presentation of GCA can be atypical and cases 
showing only anemia and raised inflammatory markers 
have been reported.
21
  A persistent dry cough can be a 
presenting symptom too, either isolated or associated 
with typical manifestations.
22
 Our case was challenging 
because the patient complained only of anemia related 
symptoms, arthralgias, and mild fever and the elevated 
inflammation markers could not be easily interpreted. 
It outlines that is it is necessary to be aware of the 
entire spectrum of symptoms of GCA in order to 
consider it in the differential diagnosis of anemia. 
Indeed, our patient initially complained of a cough, but 
this symptom was not reported later. The use of PET 
can certainly facilitate the diagnosis of GCA, but it is 
expensive, and it exposes patients to a significant 
radiation risk.  
An association between autoimmune diseases, 
including vasculitis, and MDS has been reported, 
especially in case of chronic myelo-monocytic 
leukemia and high risk MDS.
23-25
 However, in our 
patient anemia completely resolved with steroid 
treatment and she is currently doing well seven years 
after GCA diagnosis without any further therapy. 
 
Conclusion. Our case reminds clinicians they should 
always consider multiple differential diagnosis of 
anemia in the presence of systemic inflammation, 
which can be itself a cause of secondary dysplasia. 
MDS can be considered when other etiologies are 
excluded, but it should be kept in mind that the 
diagnosis is difficult, especially when only anemia is 
present, and it is mostly based on morphology and 
histopathology expertise. 
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